Sugi Predict

Sugi Predict / Compounds / SCHEMBL4560704

SCHEMBL4560704

SCHEMBL4560704

Brc1ccc2nccn2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 3/20 0.52
▸ CLK4 Q9HAZ1 3/20 0.46
▸ MAPK14 Q16539 2/20 0.46
▸ MAP4K4 O95819 2/20 0.46
▸ PRKACA P17612 2/20 0.46
▸ CDK8 P49336 2/20 0.46
▸ LRRK2 Q5S007 2/20 0.46
▸ KDR P35968 10/20 0.45
▸ RET P07949 3/20 0.45
▸ JAK2 O60674 2/20 0.45
▸ GSK3A P49840 2/20 0.45
▸ RPS6KA3 P51812 2/20 0.45
▸ LIMK1 P53667 2/20 0.45
▸ MAP2K1 Q02750 2/20 0.45
▸ ALK Q9UM73 2/20 0.45
▸ DYRK1B Q9Y463 2/20 0.45
▸ PRKCI P41743 1/20 0.41
▸ AURKA O14965 1/20 0.40
▸ DAPK3 O43293 1/20 0.40
▸ ABL1 P00519 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7514132 0.74 DYRK1A (0.52) DYRK1ACLK4MAPK14MAP4K4PRKACA
SCHEMBL1051267 0.74 DYRK1A (0.52) DYRK1ACLK4MAPK14MAP4K4PRKACA
SCHEMBL16875635 0.74 DYRK1A (0.52) DYRK1ACLK4MAPK14MAP4K4PRKACA
SCHEMBL102246 0.74 DYRK1A (0.52) DYRK1ACLK4MAPK14MAP4K4PRKACA
SCHEMBL9125832 0.74 KDR (0.62) DYRK1ACLK4MAPK14MAP4K4PRKACA
SCHEMBL5487802 0.74 DYRK1A (0.52) DYRK1ACLK4MAPK14MAP4K4PRKACA
SCHEMBL2067916 0.74 DYRK1A (0.52) DYRK1ACLK4MAPK14MAP4K4PRKACA
SCHEMBL3500436 0.74 DYRK1A (0.52) DYRK1ACLK4MAPK14MAP4K4PRKACA
SCHEMBL2068566 0.74 DYRK1A (0.47) DYRK1ACLK4MAPK14MAP4K4PRKACA
SCHEMBL877269 0.72 DYRK1A (0.50) DYRK1ACLK4MAPK14MAP4K4PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741392-A1 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF Shenzhen TargetRx Co., Ltd. (CN) 2026-05-13 — — EP disclosed
EP-4658656-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES Beone Medicines I GmbH (CH) 2025-12-10 — — EP disclosed
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-13 — — US disclosed
WO-2025007863-A1 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2025-01-09 — — WO disclosed
CN-119241532-A 1H-pyrazolo [4,3-c ] pyridine compound, composition and application thereof 深圳市塔吉瑞生物医药有限公司 2025-01-03 — — CN disclosed
US-20240360125-A9 2-SUBSTITUTED BICYCLO[1.1.1]PENTANES THE TRUSTEES OF PRINCETON UNIVERSITY 2024-10-31 — — US disclosed
US-12110294-B2 CD73 compounds GILEAD SCIENCES, INC. (US) 2024-10-08 — — US disclosed
WO-2024160276-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEIGENE, LTD. (KY) 2024-08-08 — — WO disclosed
WO-2024107393-A1 TRICYCLIC COMPOUNDS SCHRÖDINGER, INC. (US) 2024-05-23 — — WO disclosed
US-20240150353-A1 2-SUBSTITUTED BICYCLO[1.1.1]PENTANES UNIV PRINCETON (US) 2024-05-09 — — US disclosed
WO-2018017633-A1 TGF Beta RECEPTOR ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-25 — — WO disclosed
EP-2919784-B1 HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE CALITOR SCIENCES LLC (US) 2017-12-20 — — EP disclosed
CN-106632355-A Synthesis method of 6-bromoimidazo[1,2-b]pyridazine 山东友帮生化科技有限公司 2017-05-10 — — CN disclosed
CN-106632355-A Synthesis method of 6-bromoimidazo[1,2-b]pyridazine 山东友帮生化科技有限公司 2017-05-10 — — CN disclosed
EP-2919784-A1 HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE Calitor Sciences, LLC (US) 2015-09-23 — — EP disclosed
WO-2014078211-A1 HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE CALITOR SCIENCES, LLC (US) 2014-05-22 — — WO disclosed
US-20140134133-A1 HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-05-15 — — US disclosed
EP-2637660-A1 FATTY ACID SYNTHASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2013-09-18 — — EP disclosed
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC 2013-09-12 — — US disclosed
WO-2012064642-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140134133-A1 HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE PIK3R1, PIK3R3, AKT3 DYRK1A 694/4885CLK4 581/4885MAPK14 375/4885
US-20240360125-A9 2-SUBSTITUTED BICYCLO[1.1.1]PENTANES CYP1B1, BMP2, CCR1 DYRK1A 3100/4885CLK4 3831/4885MAPK14 3208/4885
US-12110294-B2 CD73 compounds ENTPD5, ENTPD1, NT5E DYRK1A 3442/4885CLK4 4839/4885MAPK14 4775/4885
US-20240150353-A1 2-SUBSTITUTED BICYCLO[1.1.1]PENTANES CYP1B1, BMP2, CCR1 DYRK1A 3100/4885CLK4 3831/4885MAPK14 3208/4885
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES DGKG, DGKA, DGKK DYRK1A 1637/4885CLK4 462/4885MAPK14 363/4885
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, FADS2 DYRK1A 4640/4885CLK4 3358/4885MAPK14 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.